Global study links liver transplant to survival gains in severe ACLF

Share

Patients with advanced cirrhosis and severe acute-on-chronic liver failure (ACLF) who underwent liver transplantation had better survival outcomes than those who were declined for transplantation, according to findings from the global CHANCE study published in the Journal of Hepatology.

Among 612 transplant recipients, 21% of those with ACLF grade 3 at transplantation and 11% of those with grade 2 died within a year without retransplantation. Among 144 patients with grade 2 or 3 ACLF who were declined for transplantation, 73% and 88%, respectively, died within a year of enrollment.

“The main message is that patients with severe ACLF, including ACLF grade 3, should not be considered ‘too sick to transplant’ by default,” co-first and corresponding author Thierry Gustot, MD, PhD, of Hôpital Universitaire de Bruxelles–Hôpital Erasme and Université Libre de Bruxelles, Brussels, Belgium, told GI & Hepatology News. “Early referral to a transplant center and a timely assessment are what make benefit possible.”

Study design and outcomes

The prospective, observational cohort study enrolled 995 adults with decompensated cirrhosis at 63 liver transplant centers across Europe, North America, Latin America, and Asia between July 2021 and October 2023. Of these, 452 were listed for transplantation with ACLF grade 2 or 3; 399 were listed with ACLF grade 1 or, if they had no ACLF, a Model for End-Stage Liver Disease score above 20; and 144 with ACLF grade 2 or 3 were declined for transplantation at the investigators’ discretion. The primary outcomes were death without retransplantation within one year after transplantation and, for patients who did not receive a transplant, death within one year after enrollment.

Under the criteria used in the study, ACLF is graded by the number of failing organs among six systems: liver, kidney, coagulation, brain, circulation, and respiration. Grade 1 involves one organ failure, grade 2 involves two, and grade 3 involves three to six. The investigators considered grades 2 and 3 severe.

Overall, 2% of transplant recipients underwent retransplantation and 12% died without retransplantation within one year of the procedure. One-year case-fatality rates without retransplantation were 10% for recipients with ACLF grade 1 and 9% for those without ACLF at transplantation. Among recipients with five or more organ failures, the rate was 42%.

An intention-to-transplant analysis counting deaths from enrollment, including those on the waiting list, also suggested a benefit for listed patients with ACLF grade 2 or 3 compared with those who were declined, according to the study.

After transplantation, patients with ACLF grade 3 had longer intensive care unit stays than other recipients — a median of 10.5 days vs. five to seven days — but similar ward stays and readmission rates. Among ACLF grade 3 recipients who were alive at one year, 89% were living at home and 2.1% required long-term renal replacement therapy, a proportion similar to that of other recipients.

In multivariable analyses, ACLF grade 3 at transplantation (vs. no ACLF) and transplantation in Asia (vs. Europe or North America) were associated with higher post-transplant mortality. Risk was similar for ACLF grade 2 vs. no ACLF and for transplantation in Asia vs. Latin America. In separate models, five or more organ failures and brain failure at transplantation were each associated with higher post-transplant mortality.

Because 89% of transplants in Asia used living donors, the investigators also modeled donor type and found that living donor transplantation was associated with higher post-transplant mortality than deceased donor transplantation. They noted the association may reflect other regional factors, including perioperative practices, listing thresholds, and the cause of cirrhosis.

Impact and implications

“The CHANCE study provides clear, consistent, and clinically decisive evidence that liver transplantation confers a substantial survival benefit in patients with ACLF, even with high grade, around the globe,” the investigators wrote. “These results directly challenge prevailing notions of futility and highlight the risk of systematic under-access to transplantation in this population. [The study] provides prospective evidence that should inform future allocation policy and listing criteria, supporting a more consistent, evidence-based, and equitable approach to transplant candidacy in patients with ACLF.”

Thierry Gustot, MD, PhD

When evaluating patients with ACLF grade 2 or 3 for transplantation, “the dynamics matter more than a single snapshot,” Dr. Gustot said. “Teams should look at how the patient responds to the first days of intensive care, which organs are failing (especially respiratory failure requiring mechanical ventilation), and whether infection is controlled.” He said frailty, comorbidities, and the likelihood of post-transplant recovery should also be weighed alongside disease severity scores. He added that delays should be minimized once a patient is listed because the window for transplantation is often short.

However, the investigators advised against routine liver transplantation in patients with ACLF grade 3 and five or more organ failures because of high post-transplant mortality. They said the finding should be interpreted with caution given the subgroup’s small size.

To better identify which patients in this subgroup may benefit, Dr. Gustot called for larger international prospective cohorts with standardized definitions and data collection. He also called for improved tools to predict post-transplant futility by combining clinical trajectories with biomarkers. And he emphasized the need for data on functional recovery, quality of life, and the impact on transplant waiting lists.

“Ethical questions of organ allocation can only be answered with such data,” he said.

The investigators noted several limitations. Post-transplant mortality did not include deaths on the waiting list, which were more common among patients listed with ACLF grade 2 or 3 at enrollment: 27.4% died or were delisted for deterioration vs. 14.5% of other listed patients. Patients who were declined for transplantation appeared sicker than those who were listed, suggesting a selection bias that propensity score matching did not eliminate. Transplant criteria were not predefined, enrollment stopped short of the planned 3,000 patients after a post hoc sample size recalculation, and some high-volume centers enrolled few patients. Only 24 patients had five or more organ failures. And because most patients — particularly the sickest — were treated in Europe and North America, the findings may not generalize to Latin America and Asia.

The study was sponsored by the European Foundation for the Study of Chronic Liver Failure; one coauthor reported study support from the Dora Roberts Foundation. Dr. Gustot contributed to the strategic board of GoLiver Therapeutics and received a travel grant from Gilead. Numerous coauthors reported research grants, consulting fees, lecture honoraria, travel grants, or advisory roles with companies including Gilead, Chiesi, Grifols, Astellas, AbbVie, and Genfit. The senior author reported founding Yaqrit, a University College London spinout, and holding stock options in Yaqrit, Hepyx, and Cyberliver.